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Abstract
Background: Classical galactosemia (CG) (OMIM #230400) is a rare disorder
of carbohydrate metabolism, due to deficiency of galactose-1-phosphate
uridyltransferase (EC 2.7.7.12). The pathophysiology of the long-term compli-
cations, mainly cognitive, neurological, and female infertility remains poorly
understood.
Objectives: This study investigated (a) the association between specific IgG N-
glycosylation biomarkers (glycan peaks and grouped traits) and CG patients
(n = 95) identified from the GalNet Network, using hydrophilic interaction
ultraperformance liquid chromatography and (b) a further analysis of a GALT
c.563A-G/p.Gln188Arg homozygous cohort (n = 49) with correlation with
Abbreviations: CG, classical galactosemia; FSIQ, Full Scale Intelligence Quotient; Gal, UDP-galactose; Gal-1-P, galactose-1-phosphate; GalNAc, N-
acetylgalactosamine; GalNet, International Galactosemia Network; GALT, galactose-1-phosphate uridyltransferase; Glc, UDP-glucose; GlcNAc, N-
acetylglucosamine; HILIC-UPLC, hydrophilic interaction ultraperformance liquid chromatography; RBC, red blood cell.
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glycan features with patient Full Scale Intelligence Quotient (FSIQ), and
(c) with galactose intake.
Results: A very significant decrease in galactosylation and sialylation and an
increase in core fucosylation was noted in CG patients vs controls (P < .005).
Bisected glycans were decreased in the severe GALT c.563A-G/p.Gln188Arg
homozygous cohort (n = 49) (P < .05). Logistic regression models incorporat-
ing IgG glycan traits distinguished CG patients from controls. Incremental die-
tary galactose intake correlated positively with FSIQ for the p.Gln188Arg
homozygous CG cohort (P < .005) for a dietary galactose intake of 500 to
1000 mg/d. Significant improvements in profiles with increased galactose
intake were noted for monosialylated, monogalactosylated, and mono-
antennary glycans.
Conclusion: These results suggest that N-glycosylation abnormalities persist
in CG patients on dietary galactose restriction which may be modifiable to a
degree by dietary galactose intake.
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Synopsis
Significant decreases in galactosylation and sialylation and increases in core
fucosylation and a decrease in bisected IgG glycans (involving the GALT
c.563A-G/p.Gln188Arg homozygous cohort) were observed in CG patients.
Incremental dietary galactose intake correlated positively with FSIQ and with
improvements in monosialylated, monogalactosylated, and monoantennary
glycan structures.
1 | INTRODUCTION
Classical galactosemia (CG) (OMIM 230400) is a rare
disorder of carbohydrate metabolism caused by
galactose-1-phosphate uridyltransferase (GALT) defi-
ciency (EC 2.7.7.12).1 Deficiency of GALT results in an
accumulation of intermediates of the galactose metab-
olism (Leloir) pathway, such as galactose-1-phosphate
(Gal-1-P), galactitol and galactonate.1 The only avail-
able current treatment option is a long-term galactose
restricted diet. Dietary intervention can be lifesaving
in the neonate. However, long-term complications per-
sist in treated adult patients to include significant cog-
nitive impairment, movement disorders, decreased
bone mineral density, and infertility in females. These
complications are present regardless of genotype or age
at the onset of treatment.1-6 The accumulation of toxic
galactose intermediates coupled with deficiency of
UDP-hexose sugars is proposed to contribute to the
development of these complications with possible
disruption of glycosylation central to the post-transla-
tional modification of protein and lipids.7,8 The current
tests of measuring red blood cell (RBC) Gal-1-P and
urinary galactitol levels, apart from predicting gross
deviations from diet and monitoring initial decreases
of RBC Gal-1-P in the neonate, do not reveal milder
deviations or correlate with clinical outcome.9-12
Selected studies have identified N-glycan assembly
and processing defects using the study of transferrin in
CG.13-15 Four adults with CG on a galactose-restricted
diet showed deviations from the control reference range
for specific plasma N- and O-glycans identified by
MALDI-TOF and quantified by HPLC-MS/MS.16
Immunoglobulin G (IgG) plays an important role in
the human immune system and modifiable N-glycans
attached to the Fc region can switch functionality of IgG
between pro- and anti-inflammatory statuses. The absence
of sialic acid changes the physiological role of IgG from
anti-inflammatory to pro-inflammatory17 and changes in
IgG galactosylation also have significant implications.18
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We previously identified N-glycan assembly defects in
neonates using serum IgG and ongoing significant N-
glycan processing defects in treated young children and
adults with galactosemia.19-23 We identified a significant
increase in core fucosylated neutral glycans and a signifi-
cant decrease in core fucosylated and afucosylated
bisected glycans in IgG glycans from galactosemia adult
Irish and Dutch CG patients23, with subsequent clinical
validation of an automated high-throughput IgG hydro-
philic interaction ultraperformance liquid chromatogra-
phy (HILIC-UPLC) method.24
We also reported the significant dysregulation of a
number of related relevant N-glycan biosynthesis genes
in peripheral blood mononuclear cells in CG patients
including the genes ALG9, MGAT1, and MGAT3.23,25
Applying the circulating IgG N-glycan markers to a
deep phenotyping study to include IQ as a measure of
intelligence, neurological examination assessing motor
development, tremor, and speech abnormalities of
56 Dutch CG patients (children and adults), statistically
significant differences were noted in specific N-glycan
peaks between patients and controls. However, specific
individual glycan peaks were not found to correlate
directly with neurological outcomes.26
The above studies have indicated that the glycosyla-
tion abnormalities in treated galactosemia patients
may be subtle and individual within a background of
individual genetic variation of glycosylation pathways.
Also overlaps between control ranges for patients and
controls in the context of individual glycosylation vari-
ation, effects of milder GALT gene variants and epige-
netic effects on glycosylation may confound direct
group comparisons for glycosylation abnormalities
between galactosemia patients as a group in compari-
son to controls.
There is ongoing controversy regarding the optimum
amount of galactose required in the diet for CG patients,
in particular for adults.6,9,11,27-34 In the recently reported
International Galactosemia Network (GalNet) Registry
outcome study of 509 CG patients, it was noted that
patients following a strict galactose-restricted diet (lactose
restricted and restrictions in fruit and vegetables) devel-
oped neurological complications more frequently
(P < .001; odds ratio [OR] 2.81 [1.64-4.50]) than patients
with a less strict diet (no restrictions of fruit and
vegetables).6
In this current study, we sought to identify if the
validated IgG N-glycan assay could be simplified by the
grouping of glycan features (e.g., fucosylation,
sialylation, measurement of agalactosylated, mono or
digalactosylated glycan peaks), and if any of these
group features could act as monitoring biomarkers to
determine optimum personalized glycosylation profiles
with differing dietary galactose intake in CG patients,
using an extended galactosemia population from the
GalNet Network. To potentially correct for the con-
founding effect of variation of the GALT genotype, we
also studied a subcohort of patients who are homozy-
gous for the “severe” CG GALT mutation, c.563A-G,
and p.Gln188Arg. As a secondary analysis, we also
sought to determine if there was any association with
significant N-glycan grouped features with measured
total Full Scale Intelligence Quotient (FSIQ) in the
GALT c563A-G, p.Gln188Arg homozygous cohort.
2 | MATERIALS AND METHODS
2.1 | Patient characteristics
Inclusion criteria: A total of 95 CG patients originating
from five centers in four countries included in the GalNet
Network were included in this study (see Table 1A for
demographic characteristics). All Dutch, Irish, and UK
patients had CG phenotypes with two pathogenic GALT
gene mutations and/or erythrocyte GALT enzyme activ-
ity below the limit of quantitation of the enzyme assay
(<3.3%; <1.1 μmol/h.gHb). A number of the Swiss sub-
jects had GALT residual activity (less than 10% of nor-
mal) (see Table 1A).
The most recent FSIQ assessment as noted by the study
clinicians assessed using standardized psychological testing
was documented for each patient. The standardized tests
used at the four centers were the Wechsler Intelligence
Scale for Children (WISC) and the Wechsler Adult Intelli-
gence Scale (WAIS) according to the age at testing. These
tests included the subdomain tests: Verbal Comprehension,
Perceptual Reasoning, Working Memory as well as the
FSIQ. FSIQ is a measure of the individual's overall cognitive
ability based on the individual's performance on all the
subtests.
The dietary galactose daily intake as recorded by the
treating clinician was based on the analysis of a detailed
food record, analyzed by Dietplan6 with the analysis of
free galactose values for fruit, vegetables, legumes, and
other possible galactose sources at three of the four
sites.11
For the Amsterdam site, the subjects maintained a
lactose-free diet with no restrictions in fruit and vegeta-
bles, with expected galactose daily intake of less than
100 mg/d.9
The control samples (n = 81) were obtained from a
pool of healthy adult volunteers, 56 from a Scottish
Orkney Island healthy population epidemiological study
and 25 from a healthy Irish population health insurance
screening panel (see Table 1A).
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2.2 | IgG N-glycan analysis
As previously reported, the IgG analysis was carried out
from prepared serum samples using Protein G plates on a
STARlet Microlab robotic liquid handling platform
linked to UPLC.22,24 Twenty-eight N-glycan peaks (GP),
previously characterized by UPLC and mass spectrometry
were identified (Figure 1).35
The glycan peaks represent the relative percentage
areas derived from the HILIC-UPLC profiles. The data are
compositional and convey the relative amounts of glycan
structures in a sample rather than the absolute
quantities.36 The glycan peak groups were grouped
according to common features of interest, as branching
(monoantennary [MA, GP1], biantennary [BA, GP2-4
+GP6-23+GP25-28] complex glycans, or oli-
gomannosylated [OM, GP5/2] glycans), galactosylation
(agalactosylated [G0, GP1-6], monogalactosylated [G1,
GP7-12+GP18-19], and digalactosylated [G2, GP13-17
+GP20-23+GP25-28] structures), sialylation (asialylated
[S0, GP1-17], monosialylated [S1, GP18-23] glycans),
fucosylation (core fucosylated [CF, GP1+GP4+GP6+GP9-
12+GP15-19+GP22-23+GP27-28] glycans), and bisected
glycans (B, GP3+GP6+GP8+GP11-12+GP14+GP17




mean (range) yearsF M
Controls N/A 81 42 39 29 (18-40)
Irish 25 5 20 35
Scottish 56 37 19 27
Patients 95 53 42 26 (16-63)
Expert centre/country
Dublin, Irelanda p.Gln188Arg/p.Gln188Arg 31 15 18 22 (16-36)
p.Gln188Arg/p.Arg333Trp 2







Maastricht, the Netherlandsa p.Gln188Arg/p.188Arg 4 7 0 20 (16-26)
p.Leu195Pro/p.Lys285Asn 3











Birmingham, UK N/A 13 6 7 31 (19-63)
aFor this cohort (n = 33 subjects from Dublin NCIMD and 7 from Maastricht), this cohort is similar to as reported in Stockmann et al, 201522 and Maratha et
al, 201623 with the exclusion of cases age under age 16 at the time of sampling.
bThis cohort is as described in Welsink et al, 2020.26
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+GP21+GP23+GP26+GP28). GP5/2 denotes that the oli-
gomannosylated glycans represent approximately half of
the GP5 peak. Other specific features were also investi-
gated: core fucosylated neutral glycans (Fn, GP1+GP4
+GP5+GP9-10+GP16), core fucosylated bisected neutral
glycans (FBn, GP6+GP11-12+GP17), and afucosylated
bisected neutral glycans (Bn, GP3+GP8+GP14).
2.3 | Statistical analysis
SPSS version 25 (SPSS Inc, Chicago, Illinois) and R 4.0.0
(R Core Team, 2020) were used to perform all statistical
analyses. Medians and ranges were presented. A multi-
variate analysis test was used to assess differences in
values (GP peaks and groups) between cases and controls
followed by the use of the Tukey post hoc test.
To explore any association between individual N-
glycan peaks and FSIQ, a linear regression approach was
used. Given the relatively large number of covariates (N-
glycan peaks) compared to the sample size, variable
selection was initially applied using linear LASSO regres-
sion with cross-validated mean square error minimiza-
tion to select covariates that best explain the continuous
response variable, FSIQ. N-glycan peaks were standard-
ized to avoid scaling issues and included as continuous
independent variables along with patient daily galactose
intake treated as a categorical variable with three levels
of intake: <200, 200-500, and 501-1000 mg galactose per
day. Subsequent to variable selection, the association
between FSIQ and selected covariates was analyzed using
ordinary least squares regression. Proportion of variance
explained (R2) and individual effect estimates, along with
their confidence intervals, were reported.
To assess the associations between galactosemia and
relevant features in the case-control dataset, the individ-
ual N-glycan peaks associated with each feature were
included in logistic regression models, one for each fea-
ture, which had the case-control grouping factor as
response variable. N-glycan peaks were standardized to
avoid scaling issues.
The cross-validated C-statistic and McFadden's
pseudo-R2 were reported for each model. To assess gener-
alization error caused by model overfitting, the C-
statistics and their standard deviations were calculated
using 10-fold 5X-repeated cross validation.
We then analyzed whether galactose intake caused
a difference in the grouped features for the p.
Gln188Arg homozygous group (n = 49). The Shapiro-
Wilk test of normality was initially conducted to assess
normality of group distributions. A one-way ANOVA
test was used for parametric data; the Kruskal-Wallis
test was used for nonparametric data. Bonferroni cor-
rection was used to control for the type 1 error rate due
to multiple comparisons.
3 | RESULTS
The patient cohort for this study is described in Table 1A.
The most common GALT genotype is homozygosity for
the p.Gln188Arg GALT gene pathogenic variant (n = 50).
The FSIQs as most recently recorded and available for
subjects (n = 49) was recorded. Of the 49 most recent
assessments that were available, 71% included the adult
WAIS assessment (age of testing 16-36), and 29%
included the WISC assessment (age of testing 8-15).
According to the International Standard Classification of
Education (ISCED) scale as used in the GalNet Registry6
only 14 of 47 individuals with available data (30% of
total) achieved a level of education higher than ISCED
3 (upper secondary education).
TABLE 1B Full Scale Intelligence Quotient (FSIQ) scores and
daily intake of galactose for the genotype p.Gln188Arg/pGln188Arg






FSIQ 49 78 47-126
Daily intake of galactose
<200 mg 29 59.2
200-500 mg 10 20.4
501-1000 mg 10 20.4
FIGURE 1 Representative hydrophilic interaction
ultraperformance liquid chromatography (HILIC-UPLC)
chromatogram of released undigested human immunoglobulin G
(IgG) N-glycome from classical galactosemia (CG) patients. The
main glycan structures in each glycan peak (GP1-28) are pictured
in the box insert
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TABLE 2 N-glycan peaks of significance in CG patient groups




p.Gln188Arg (n = 49)
Controls
(n = 81)
P-values (CG vs controls/p.Gln188Arg/
p.Gln188Arg vs controls) Main glycans
GP1 0.49 (0.16-1.49) 0.51 (0.16-1.05) 0.66 (0.26-1.95) <.0005 FA1
GP2 0.70 (0.36-1.26) 0.76 (0.42-1.26) 0.79 (0.45-1.01) <.0005/.087 A2
GP3 0.31 (0.05-1.61) 0.39 (0.09-1.25) 0.39 (0.22-0.57) <.05/.683 A2B
GP4 21.30 (12.54-33.81) 21.64 (12.54-33.11) 18.80 (8.60-36.15) <.0005/<.005 FA2
GP5 0.13 (0.01-0.23) 0.13 (0.02-0.21) 0.19 (0.01-0.26) <.0005 M5
GP8 0.26 (0.01-0.52) 0.23 (0.01-0.52) 0.27 (0.01-22.20) <.05 A2BG1
GP12 0.54 (0.26-1.22) 0.49 (0.29-0.82) 0.53 (0.34-1.04) .789/<.005 FA2[3]BG1
GP18 0.26 (0.22-2.75) 0.34 (0.09-2.56) 0.41 (0.22-2.75) <.0005 FA2[6]G1S1
GP19 2.14 (0.51-3.54) 1.98 (0.81-2.90) 2.40 (0.51-3.54) <.0005 FA2[3]G1S1
GP20 0.75 (0.13-2.54) 0.79 (0.24-1.28) 0.86 (0.13-2.54) <.005/.062 A2G2S1
GP22 7.52 (1.49-12.41) 7.79 (3.53-12.31) 8.76 (1.49-12.41) <.05/.151 FA2G2S1
GP24 0.04 (0.01-0.23) 0.04 (0.01-0.23) 0.06 (0.03-0.36) <.0005/<.005 n.d.
GP25 0.49 (0.13-1.34) 0.53 (0.14-1.28) 0.56 (0.06-1.29) <.05/.452 A2G2S2
GP26 0.14 (0.04-0.33) 0.12 (0.04-0.33) 0.11 (0.04-0.70) <.05/.618 A2BG2S2
B. Derived features from all glycan peaks measured
Features
CG
patients (n = 95)
p.Gln188Arg/p.
Gln188Arg (n = 49)
Controls
(n = 81)
P-values (CG vs controls/
p.Gln188Arg/p.Gln188Arg vs
controls)
CF 95.30 (91.80-97.21) 95.41 (91.81-97.06) 95.03 (63.41-97.15) <.005/<.05
OM 0.07 (0.01-0.12) 0.06 (0.01-0.010) 0.10 (0.01-0.13) <.0005
MA 0.49 (0.16-1.49) 0.51 (0.16-1.05) 0.66 (0.26-1.95) <.0005
BA 99.34 (98.30-99.72) 99.34 (97.95-100.08) 99.09 (97.81-99.71) <.0005
G0 27.00 (17.28-45.97) 27.46 (18.32-39.73) 25.50 (13.53-46.03) <.005
G1 39.66 (32.57-44.31) 39.47 (32.57-42.80) 40.11 (32.78-43.15) .163/<.05
G2 32.77 (18.46-46.91) 32.92 (19.35-44.73) 34.56 (21.17-49.80) <.05/.054
S0 84.59 (71.85-92.34) 84.37 (74.08-91.34) 82.41 (74.49-88.60) <.0005/<.005
S1 12.43 (6.59-20.26) 12.45 (7.21-18.61) 14.69 (9.53-19.18) <.0005
S2 2.90 (1.06-7.78) 2.90 (1.07-7.15) 2.84 (1.67-6.20) NS
B 15.16 (9.48-18.66) 14.51 (9.48-18.66) 15.20 (10.92-38.71) .194/<.05
Fn 70.26 (60.63-78.34) 70.32 (55.86-78.34) 67.82 (29.72-77.10) <.0005/<.005
Fbn 10.84 (6.26-19.81) 10.34 (6.26-15.89) 11.07 (2.88-16.53) NS
Bn 0.69 (0.33-1.90) 0.76 (0.33-1.69) 0.85 (0.44-22.50) NS
G0/G1 0.69 (0.48-1.29) 0.70 (0.50-1.08) 0.65 (0.37-1.40) <.0005
G0/G2 0.82 (0.37-2.49) 0.82 (0.41-2.05) 0.73 (0.27-2.17) <.005/<.05
G0/G1/
G2
0.020 (0.010-0.070) 0.021 (0.011-0.050) 0.018 (0.007-0.066) <.005
Notes: Main glycans were assigned as described in Pucic et al.35 N-glycan features were calculated as described in Materials and Methods. Data reported in
median and ranges. GPs with gray highlighted areas are increased and GPs without highlighted areas are decreased in CG patients. Only one P-value is listed if
both comparisons display the same significance.-
Abbreviations: All N-glycans have two core GlcNAcs; F at the start of the abbreviation indicates a core fucose α1,6-linked to the inner GlcNAc; Mx, number (x)
of mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl core; B, bisected GlcNAc linked β1,4 to β1,3 mannose; Gx, number (x) of β1,4
linked galactose on antenna; Sx, number (x) of sialic acids linked to galactose. All sialic acids are linked α2-6 to galactose. Glycan terminology abbreviations
used: Sialylation: S0 (neutral glycans), S1 (monosialylated), S2 (disialylated), Galactosylation: G0 (agalactosylated), G1 (monogalactosylated), G2
(digalactosylated). Branching: MA, monoantennary; BA, biantennary. OM, oligomannose. Fucosylation: CF, core-fucose. Bisecting glycans: B, total bisecting
glycans. Other specific features: Bn, afucosylated bisected neutral glycans; FBn, core fucosylated bisected neutral glycans; Fn, core fucosylated neutral glycans.
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The approximate daily galactose intake as available
and as reported by the treating centers was grouped for
49 of the p.Gln188Arg homozygotes as follows: Group 1
(n = 29): <200 mg; Group 2 (n = 10): 200-500 mg; Group
3 (n = 10): 501-1000 mg.
The serum IgG N-glycome from all patients was
released using a high-throughput method and resulting
chromatograms were separated into 28 peaks
(Figure 1).22,24 Glycan features such as branching,
fucosylation, galactosylation, and sialylation were also
determined.
Comparing CG/p.Gln188Arg/p.Gln188Arg homozygotes
with controls, several peaks and features were significantly
altered, namely glycan peaks GP4 and GP26 were increased
and GP1, 2, 3, 5, 8, 12, 18, 19, 20, 22, 24, and 25 were
decreased (Table 2A). In the derived (grouped) features,
core fucose (CF), biantennary (BA), agalactosylated (G0),
neutral (S0), and core fucosylated neutral glycans (Fn) were
increased and oligomannose (OM), monoantennary (MA),
mono and digalactosylated (G1, G2), monosialylated (S1),
and bisected (B) glycans were decreased (Table 2B). All
G0/G1, G0/G2, and G0/G1/G2 ratios were increased in CG
patients (Table 2B).
When the overall CG cohort (all genotypes) were
compared to the p.Gln188Arg/p.Gln188Arg cohort, the
significant changes in the glycomes were similar, which
mostly reached significance in the whole cohort, possibly
due to higher numbers, but the same trend was observed
also in the p.Gln188Arg/p.Gln188Arg cohort even if not
always statistically significant (Table 2A and 2B). The
exceptions were GP12, monogalactosylated glycans (G1),
and total bisected glycans (B), which were significantly
decreased only in the p.Gln188Arg/p.Gln188Arg cohort
(Table 2A and 2B).
To further explore the association between the glycan
features and CG, a series of logistic regression models
were used as described in the Methods section. This was
to quantify the combined ability of the individual peaks
of each glycan feature to classify a p.Gln188Arg GALT
homozygous galactosemia patient from a healthy control.
The results indicate that the S0 and BA features have
the strongest association with CG as determined by their
cross validated c-statistics and pseudo-R2s, both of which
indicate a strong association (Table 3). Larger cohorts
may show a stronger distinction in associative perfor-
mance between these models.
For the p.Gln188Arg/p.Gln188Arg homozygotes as a
group for analysis of correlation with FSIQ, a positive corre-
lation was observed for galactose intake and for branched
glycans (R = 0.397, P = .006 for galactose intake and
R = 0.35 for branched glycans). The result for branched gly-
cans was deemed to be too low to warrant further analysis.
TABLE 3 Tenfold cross-validated
C-statistics and McFadden's pseudo-R2
for differentiation of p.Gln188Arg
GALT homozygotes from controls using
glycan features
Feature C-statistic C-statistic SD Pseudo R2 Pseudo R2 SD
S0 0.917 0.082 0.47 0.24
BA 0.879 0.079 0.33 0.21
G1 0.870 0.066 0.27 0.15
CF 0.869 0.063 0.27 0.12
Fn 0.868 0.109 0.43 0.20
G0 0.844 0.101 0.23 0.16
G2 0.838 0.089 0.18 0.11
S1 0.831 0.092 0.21 0.18
OM 0.806 0.108 0.23 0.20
B 0.735 0.109 0.12 0.08
MA 0.724 0.152 0.12 0.17
S2 0.658 0.142 0.03 0.04
Bn 0.508 0.157 0.03 0.03
FBn 0.504 0.138 0.03 0.05
TABLE 4 Association of galactose intake with IQ in p.Gln188Arg/p.Gln188Arg cohort
Galactose intake
(<200 mg gal is the baseline) Estimated mean change IQ 95% CI P-value (uncorrected)
200-500 mg 1.56 12.17 to 15.30 .820
501-1000 mg 22.99 9.78-36.19 .001
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Galactose intake was subsequently included as a covari-
ate in a linear regression model with FSIQ as the response
variable (Table 4). When the estimated mean increase in
FSIQ for 200-500 and 501-1000 mg galactose intake was
compared to <200 mg galactose intake (P < .005), only the
501-1000 mg galactose intake group showed a statistically
FIGURE 2 Boxplots of glycan features for controls and patients with galactose intakes of <200, 200-500, and 501-1000 mg. The boxplots
display the median and ranges. A, Controls are shown in blue; patients are shown in yellow. B, Significant difference in values according to
galactose intake are shown (P < .05)
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significantly higher FSIQ compared to the <200 mg galac-
tose intake group (Table 4). However, the contemporary
galactose intake could only explain 23% of the FSIQ vari-
ability between patients (R2: 0.23).
The analysis of differences between galactose intake
in glycan peaks and groups for the three groups of p.
Gln188Arg/p.Gln188Arg homozygotes (n = 49) with
differing galactose intake was assessed (Figure 2;
Table 5). The trend for the majority of GPs was to
approach the control range for both degrees of galac-
tose liberalization. All resultant values were in the con-
trol ranges for the GPs (see Table 2A). However,
statistical significance differences were only reached
for the G1, S1, and MA groups. For the G1 feature, for
group 2 (galactose intake of 200-500 mg day), this
group had significantly lower scores (36.66
[32.57-40.42]) vs group 3 (intake 501-1000 mg/d) (39.91
[37.28-42.34]), P ≤ .05. For the S1 feature, group 2 had
significantly higher scores (14.05 [11.83-17.39]) vs
group 1 (12.08 [7.23-18.61]) (P ≤ .05), approaching the
median of the control range. For the MA feature, group
2 had a significantly higher level 0.69 (0.43-0.91) than
group 1 (P < .05) with values approaching the median
of the control range in group 2.
The previously reported G0/G1, G1/G2, and G0/G1
and G2 ratios were not informative in discriminating
galactose tolerance.
4 | DISCUSSION
CG is considered to be a secondary glycosylation disor-
der. The effects of galactose restriction in the intoxicated
neonate are well documented. Also there is evidence that
there are differences in how patients of identical GALT
genotype manifest N-glycan profiles with increased galac-
tose intake.20,31
This study aimed to identify if grouped glycan (com-
plex carbohydrate) IgG features in adult CG patients
ascertained from the GalNet Consortium could serve as
predictive clinical biomarkers for galactose tolerance and
also as a secondary analysis to look at IQ (FSIQ) as an out-
come with IgG features for the Q188R homozygous group.
In the current study, we have replicated our previous
findings showing a decrease in galactosylation in CG as
demonstrated by significantly increased ratios of G0/G1,
G0/G2, and G0/G1/G2 (Table 2B) consistent with the
report by Stockmann et al.22 We also report significant
increases in the glycans GP4 and 26 and decreases in
GP1, 5, 18, and 24 (Table 2A); consistent with findings by
Maratha et al and Welsink et al, respectively.23,26 In this
cohort, we also report additional significant peaks (GP2,
4, 8, 12, 19, 20, 22, and 25). There are also other glycan
peaks which were previously found to be significant in
our previous studies, but were not shown to be significant
in this cohort (GP7, 11, 15, and 21; Table 2A).
TABLE 5 Association of IgG glycome (grouped features) with galactose intake in p.Gln188Arg/p.Gln188Arg cohort
Galactose daily intake <200 mg (n = 29) 200-500 mg (n = 10) 501-1000 mg (n = 10) P-value
CF 95.14 [91.81-97.06] 95.34 [93.12-96.23] 96.00 [93.56-96.97] .156
OM 0.07 [0.01-0.10] 0.06 [0.01-0.07] 0.06 [0.01-0.085] .055
MA 0.47 [0.23-1.05] 0.69 [0.43-0.91] 0.43 [0.16-1.03] .036*
BA 99.35 [99.1-100.08] 99.13 [98.74-99.72] 99.48 [97.92-99.60] .175
G0 26.58 [20.78-39.73] 29.12 [18.32-35.36] 29.12 [23.54-38.06] .471
G1 39.57 [34.28-41.66] 36.66 [32.57-40.42] 39.91 [37.28-42.34] .025*
G2 33.51 [19.35-42.61] 32.19 [24.51-42.53] 31.41 [21.93-37.1] .526
S0 85.26 [74.08-91.34] 81.72 [77.33-86.22] 84.63 [81.65-89.01] .088
S1 12.08 [7.23-18.61] 14.05 [11.83-17.39] 12.09 [9.22-14.52] .047*
S2 2.72 [1.07-7.15] 3.76 [1.92-5.7] 2.94 [1.77-3.86] .158
B 15.27 [10.27-18.66] 13.64 [11.23-15.29] 13.16 [9.48-17.82] .090
Fn 69.45 [55.86-78.34] 69.04 [63.56-74.27] 72.53 [68.62-77.12] .082
FBn 10.87 [6.27-15.89] 9.84 [8.22-11.95] 9.76 [6.26-12.67] .092
Bn 0.79 [0.38-1.69] 0.72 [0.41-0.96] 0.72 [0.33-1.56] .203
G0/G1 0.67 [0.55-0.99] 0.82 [0.50-1.08] 0.72 [0.60-0.95] .305
G0/G2 0.79 [0.49-2.05] 0.84 [0.41-1.23] 0.94 [0.63-1.74] .466
G0/G1/G2 0.02 [0.01-0.05] 0.02 [0.01-0.03] 0.03 [0.02-0.04] .546
*Significant at P ≤ 0.05 level. Data are presented as medians and ranges.
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The glycome of immunoglobulins is noted to be highly
variable with high heritability37 with polymorphisms of the
glycan genes encoding the glycosyltransferases ST6GAL1,
B4GALT1, FUT8, and MGAT3, noted to represent the most
important loci associated with variation in IgG traits.38 Thus,
differences in background glycosylation pathways may
account for individual variation in glycan peaks as shown
by the wide ranges of values of controls in Table 2A.
In this study, we did not note significant differences
in gender or age in the study and control groups. We con-
sidered it to be more practical/informative thus to ana-
lyze differences in grouped glycan features (Table 2B)
rather than the individual glycan peaks.
To decrease confounders of possible residual enzy-
matic activity for some patients in the total cohort, our
final analysis with FSIQ and dietary tolerance was based
on homozygotes only for p.Gln188Arg, as CG patients
with this genotype are well described in the literature as
having a severe CG phenotype. While studying the p.
Gln188Arg homozygous cohort may eliminate some of
these confounders, we have however also noted signifi-
cant contemporary differences in glycosylation in siblings
homozygous for p.Gln188Arg emphasizing the potential
significance of epigenetic effects on glycosylation and
alternate accessory glycosylation pathways.19,20
For the groups feature analysis, the total bisected gly-
cans (B) were found to be decreased in the p.Gln188Arg/
p.Gln188Arg cohort (Table 2B) consistently with decrease
in the MGAT3 gene expression which we previously
reported.23 It is considered that the bisecting N-
acetylglucosamine (GlcNAc) structure represents a spe-
cific type of N-glycosylation modification involved in bio-
logical processes including cell adhesion, fertilization,
neurite outgrowth, and tumorigenesis.18
The observed increase in core fucosylation is consis-
tent with our previous findings, namely the increases in
Fn and total fucosylation (CF) (Table 2B).
When the total study cohort was compared to the p.
Gln188Arg cohort, the significant changes in the glycomes
were consistent, mostly reaching significance in the whole
cohort (Table 2A), possibly due to higher numbers. How-
ever, the same trend was observed also in the p.Gln188Arg/
p.Gln188Arg cohort; though with smaller numbers not
always reaching significance.
Although we also noted significant findings of ongoing
abnormal branching, fucosylation, and galactosylation of
IgG N-glycans among treated CG patients, we only found a
direct correlation between branching glycans and galactose
intake with the measured IQ of these patients, with only
galactose intake being statistically significant. This finding
is not unexpected. While there are statistically significant
differences between specific glycan peaks and grouped fea-
tures between treated CG and controls, the measured
outcome (FSIQ) is likely influenced by prenatal galactose
exposure or intoxication, neonatal galactose intoxication,
and possible ongoing abnormalities of systemic N-glycan
processing abnormalities and cell signaling abnormalities.
In this study, we found a decrease in sialylated gly-
cans in the CG patients, with the most significant correla-
tion existing between the non sialylated (S0) glycans and
the phenotype of CG.
We consider that the role of sialic acid and galactose in
glycan processing as central determinants of the outcome
measured (IQ) has a strong biological plausibility.39-41
Many of the linear and branched glycans on cell sur-
face glycoproteins and glycolipids of vertebrates are ter-
minated with sialic acids, nine-carbon sugars with a
carboxylic acid, a glycerol side-chain, and an N-acyl
group that provide for varied molecular interactions.
Sialic acid is found in large quantities in human milk oli-
gosaccharides as sialylated-glycoconjugates and is an
essential component of brain gangliosides and sialylated
glycoproteins, particularly as precursors for the synthesis
of the polysialic acid glycans that posttranslationally
modify the cell membrane associated neural cell adhe-
sion molecules). In addition, gangliosides, sialylated
glycosphingolipids, are the most abundant sialoglycans of
nerve cells. The multiple antennae of classical “complex
type” N-linked glycans are often terminated with “NeuAc
α2–3 (or α2-6) Gal β1-4 GlcNAc” sequences. The most
abundant O-glycans are bound to proteins via an N-
acetylgalactosamine (GalNAc)-Ser/Thr linkage.40
Abnormalities of sialic acid biosynthesis are embryoni-
cally lethal in mice, and are associated with a variety of
human diseases.42,43 The four predominant gangliosides in
the brain share the same neutral glycan core (Gal β1-3
GalNAc β1-4 Gal β1-4 Glc β1-1 Cer) with varying numbers
of sialic acids attached to the internal and terminal galac-
tose residues. Genome-wide linkage analysis implicates
sialylation as a determinant of higher cognitive functions.
In particular, the ST3GAL3 enzyme transfers sialic
acids to terminal Gal residues in β1-3 or β1-4 linkage to
GlcNAc or in β1-3 linkage to GalNAc. This is a character-
istic of O- and N-linked glycoproteins and gangliosides.44
We have previously demonstrated dysregulation of this
gene and other sialyltransferases in CG patients.45
The long-term outcomes in treated patients with CG
have indicated a high incidence of lower intellectual out-
come, and more recently a high percentage of motor
symptoms including dystonia and tremor in children and
adults.2-6,26,46 In parallel with this, a number of studies
have indicated gray and white matter changes in MRI
scans of the brain in individuals with CG.26,47,48 It is cur-
rently unclear if the white and gray matter changes
observed in patients with CG are progressive. Deficiency
of glycolipids containing galactose or GalNAc has been
TREACY ET AL. 85
demonstrated in a postmortem brain examination of a
patient with galactosemia.49 In addition to galactose,
sialic acid is essential for glycolipid synthesis.
Fucosylated, galactosylated, and sialylated complex N-
glycans have been identified as significant constituents of
the human brain glycome.49,50
For the grouped features (listed in Table 2B),
although the G ratios previously reported significantly
differentiate CG patients from controls, these ratios did
not significantly differentiate patients with differing
galactose intake (Table 5). The features which were sig-
nificantly different between the subgroups of patients
with differing galactose dietary intake were the features
S1 (P = .047), G1 (P = .025), and MA (P = .036). In con-
junction with the informative results in Tables 2B and 4,
it may be feasible to utilize the features S0, S1, G0, and
G1 as biomarkers of galactose tolerance, individualized to
each patient as their own control.
For the combined data set, the study sample in the
two smaller groups (n = 10) limit the conclusions in this
regard for the group in general, and as stated earlier there
is an overlap between controls and cases for the reference
range. Although this study involving multiple partners of
the GalNet Network is the largest study of CG (n = 95
patients including 49 Q188R homozygotes), a larger con-
trolled study would be required to study this further.
5 | STUDY LIMITATIONS
As stated above, as a rare disease, the study number is still
limited with patients studied with possible differing genetic
backgrounds. Thus, a larger study is required to test the
clinical utility of the proposed biomarkers to examine galac-
tose tolerance in these individuals. Larger cohorts may
show a stronger distinction in associative performance
between the models used. For this study, the analysis of
galactose dietary intake was based on dietary analysis docu-
mentation available at the time of blood sampling. Accurate
retrospective quantitation of galactose intake remains prob-
lematic.51 Also the analysis presented likely represents the
galactose intake prior to the sampling. It cannot provide
insight into early life or life-long galactose intake which
may directly affect neurological outcomes.
6 | CONCLUSIONS
In this study, we have described characteristic fea-
tures in galactosemia patients, namely an increase in
core fucosylation and a decrease in galactosylation of
IgG as well as a decrease in bisected glycans in the
GALT gene p.Gln188Arg homozygous cohort. Figure 3
summarizes these results, galactose intake correlation
with FSIQ, with improvements of monosialylated,
monogalactosylated, and monoantennary glycans.
We propose that galactosylation and sialylation of
glycans of major physiological relevance may be modi-
fied by moderate exogenous galactose dietary intake.
These studies provide further insight from a rare
inborn error of metabolism into the central role of
galactosylation in glycan synthesis. The influence of
these changes on corresponding protein/cell function
needs to be further delineated so that management of
affected individuals can be tailored accordingly.
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